SCHEMBL6474062

SCHEMBL6474062

CCCS(=O)(=O)NCC(C)Oc1ccc(-c2ccc(-c3cccs3)cc2)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PSMB5 P28074 2/20 0.43
PPARG P37231 2/20 0.41
PPARA Q07869 2/20 0.41
GRIA4 P48058 1/20 0.40
KDM4E B2RXH2 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
MEN1 O00255 1/20 0.39
MAPT P10636 1/20 0.39
KMT2A Q03164 1/20 0.39
CA12 O43570 2/20 0.36
CA2 P00918 2/20 0.36
CA1 P00915 1/20 0.36
MMP2 P08253 1/20 0.36
CA9 Q16790 1/20 0.36
CA14 Q9ULX7 1/20 0.36
GRIA2 P42262 2/20 0.35
MTNR1A P48039 3/20 0.35
MTNR1B P49286 3/20 0.35
HPGD P15428 2/20 0.34
RAB9A P51151 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6474502 0.95 PSMB5 (0.42) PSMB5PPARGPPARAGRIA4KDM4E
SCHEMBL6482324 0.87 GRIA4 (0.46) GRIA4KDM4EMAPTCA12CA2
SCHEMBL6474055 0.85 GRIA2 (0.44) PSMB5PPARGPPARAGRIA4KDM4E
SCHEMBL6475297 0.84 GRIA4 (0.48) PPARGPPARAGRIA4SMN1; SMN2MAPT
SCHEMBL6474393 0.82 GRIA4 (0.43) PPARGPPARAGRIA4MEN1MAPT
SCHEMBL6482161 0.82 MTNR1A (0.49) GRIA4KDM4EMMP2MTNR1AMTNR1B
SCHEMBL6475868 0.81 GRIA4 (0.48) GRIA4KDM4ECA12CA2GRIA2
SCHEMBL6528247 0.81 GRIA4 (0.48) GRIA4KDM4ECA12CA2GRIA2
SCHEMBL6472661 0.81 GRIA4 (0.42) PPARGPPARAGRIA4MAPTCA2
SCHEMBL6475311 0.81 GRIA4 (0.47) GRIA4MAPTCA2CA1MTNR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6911476-B2 Sulfonamide derivatives ELI LILLY AND COMPANY (US) 2005-06-28 US claimed
US-20030225266-A1 Sulfonamide derivatives ELI LILLY AND COMPANY 2003-12-04 US claimed
EP-1265857-A1 SULFONAMIDE DERIVATIVES ELI LILLY AND COMPANY (US) 2002-12-18 EP claimed
WO-2001068592-A1 SULFONAMIDE DERIVATIVES ELI LILLY AND COMPANY (US) 2001-09-20 WO claimed
US-6911476-B2 Sulfonamide derivatives ELI LILLY AND COMPANY (US) 2005-06-28 US disclosed
US-20030225266-A1 Sulfonamide derivatives ELI LILLY AND COMPANY 2003-12-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225266-A1 Sulfonamide derivatives GRIN2A, GRM2, GRIA2 PSMB5 1605/4885PPARG 828/4885PPARA 1066/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.